TRIAL DETAIL

A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies

Drug:
Trial Name:
A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date
Age of Trial (yrs)
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
REFMAL144
Sponsor:
Sarah Cannon Research Institute Novartis
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This drug inhibits PI3K but not mTOR.

Trial Links

Trial Results
 
 

Drug Information
Trials at Sarah Cannon Research Institute
 
ASCO 2010 - Simultaneous targeting of the androgen receptor and PI3K/mTOR pathway in androgen-dependent and androgen-independent prostate cancer cells.
 

Trial Sites

Name
Address
City
State
Zip
Country
3322 West End Avenue
Nashville
TN
37203
USA